Incyte Corp (INCY.OQ)
23 Feb 2018
* INCYTE REPORTS 2017 FOURTH-QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL GUIDANCE AND UPDATES ON KEY CLINICAL PROGRAMS
* INCYTE UPDATES CONFERENCE CALL TIME TO REPORT FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS Source text for Eikon: Further company coverage:
* SYROS PHARMACEUTICALS - ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING
* INCYTE CORPORATION RECOMMENDS SHAREHOLDERS REJECT MINI-TENDER OFFER BY TRC CAPITAL CORPORATION
BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement
* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT
* Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi®) for the treatment of essential thrombocythemia
* Incyte reports 2017 third-quarter financial results and updates on key clinical programs
LONDON AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.
LONDON, Oct 31 AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.
* Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer